Welcome Stockaholics!

We are a new and fast growing financial forum! Sign up for free and let's talk stocks!

  1. Do you want to help develop this community? We are looking for contributions from investors and traders like you! What stocks do you follow? What is hot right now? Sign up and get in on the ground floor of the newest, fastest growing financial forum!
    Dismiss Notice
  2. You will notice a live chat widget on the right. Click in to join us and lets hear about how you nailed that last UWTI trade!
    Dismiss Notice

AXSM - Axsome Therapeutics

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by Biotechmaster, Mar 22, 2017.

  1. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    106
    Likes Received:
    4
    Very attractive and massive undervalued Biotech Stock with many Major News on the way . Axsome has 4 Phase 3 clinical trials ongoing in various indication targeting very large Markets .This Stock is brutally undervalued with Market cap of $83 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) over 50% of O/S is owned by Insider and Institutions which is a good sign .

    This undiscovered goldmine could be the next 10 bagger gem if just oneof their 4 Phase 3 program is successful .GL


    Axsome (AXSM)

    Market-Cap: $83 Million
    Cash: $50.6 Million
    Price:$3.60

    Shares Out: 23 Million


    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)


    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)



    New Presentation
    http://redirect.viglink.com/?key=bb...25/254022/Axsome_Presentation_14_Mar_2017.pdf


    Major Shareholders

    Herriott Tabuteau, MD 7 351 729 38,4%
    Fidelity Management & Research Co. 2 361 625 12,3%
    JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
    Mark Coleman, MD 647 998 3,38%
    BlackRock Fund Advisors 426 837 2,23%
    Stifel Trust Co., NA 415 279 2,17%
    The Vanguard Group, Inc. 272 189 1,42%
    Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
    JPMorgan Investment Management, Inc. 156 625 0,82%
    SSgA Funds Management, Inc. 134 688 0,70%


    [​IMG]
     
  2. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    5,286
    Likes Received:
    795
    [​IMG]
    Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).
     
  3. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    106
    Likes Received:
    4
    StockJock-e likes this.
  4. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    5,047
    Likes Received:
    1,039
    Nice bounce today!

    Looks like the dip buyers are getting paid!
     
  5. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    106
    Likes Received:
    4
    maybe the cheapest Nasdaq Biotech you can get with 5x Phase 3 in various indications and a laughable Market cap of $85 Million and $50 Million in cash .The fair value should be at $8-10 right now for this unknown Biotech .

    Latest stock market analyst ratings:

    Brean Capital began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 20 price target on the stock.

    Axsome Therapeutics, Inc. had its “” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 27 price target on the stock.

    Cantor Fitzgerald began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 13 price target on the stock.
     
  6. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    106
    Likes Received:
    4
    Hey guys if you own shares of this low float stock then please put a high GTC sell order in to prevent your shares from being borrowed to short . This will help to drive this brutally undervalued stock much higher .Thank You

    How to Prevent your Shares Holdings from being Shorted
    http://www.contracts-for-difference.com/Borrowing-lending-shares.html
     
  7. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    106
    Likes Received:
    4
  8. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    106
    Likes Received:
    4
    looks like small consolidation ongoing after nice move in last day so any dip is a great buying opp
     
  9. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    106
    Likes Received:
    4
    Good news could come on next Wednesday

    Axsome Therapeutics, Inc. at 16th Annual Needham Healthcare Conference (Live)
    April 5, 2017 at 8:40 a.m. ET
     
  10. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    106
    Likes Received:
    4
    Looks like tree shaking ongoing to steal more cheap shares . AXSM is definitely one of the cheapest Nasdaq biotech i ever have seen before in last 18 years .GL


    Market cap: $84 million
    Cash: $50.6 Million

    NEW Presentation April
    http://phx.corporate-ir.net/Externa...9NjY0Mzk1fENoaWxkSUQ9MzcyMTk4fFR5cGU9MQ==&t=1

    Financial guidance: Recent financing extends estimated cash runway into the first quarter of 2019.


    AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)
     
  11. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    106
    Likes Received:
    4
    Very nice accumulation ongoing in last days ,this one will be over $10 before year end especially with positive phase 3 results next quarter .This is next ACAD in the making here
     
  12. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    106
    Likes Received:
    4
    Any chart technical here ? looks like breakout is imminent
     
  13. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    106
    Likes Received:
    4
    there we go guys we are over $4 ,, this stock is what i call a once in a lifetime opp this stock should be at $20 right now not at laughable $4 .

    5 Phase 3 Programs two of them targeting very large Markets with NO approved Drugs .

    Marketcap: $90 Million
    Cash: $50 Million
    Price: $3.95

    New Presentation
    http://phx.corporate-ir.net/Externa...9NjY0Mzk1fENoaWxkSUQ9MzcyMTk4fFR5cGU9MQ==&t=1

    AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3 Phase 3 commenced March 2016. Interim analysis due 3Q 2017.

    AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) Phase 3 Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.

    AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3


    AXS-05 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3 Phase 2/3 to be initiated 2Q 2017.

    AXS-05 STRIDE-1 Treatment resistant depression Phase 3 Phase 3 initiated March 2016. Top-line data due 1Q 2018.
     
  14. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    106
    Likes Received:
    4
    Bigger jump in share price coming once it breaks the MA(50) at $4.36 .
     
  15. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    106
    Likes Received:
    4
    Bullish crossover in MACD and Stochastic oscillator.

    [​IMG]
     
  16. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    106
    Likes Received:
    4
    Need to break the MA(50) at $4.24 then $5+ coming
     
  17. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    106
    Likes Received:
    4
    T0rm3nted likes this.
  18. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    106
    Likes Received:
    4
  19. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    106
    Likes Received:
    4
    Well written article out by J.Napodano

    Should You Invest In Axsome Therapeutics? Monday, May 8, 2017
    http://www.talkmarkets.com/content/...you-invest-in-axsome-therapeutics?post=134346

    Final Thoughts

    Axsome is very interesting to me. The company has four active Phase 3 clinical trials with two drug candidates. AXS-05 targets a host of mechanisms in the CNS that are clinically and commercially proven to be effective for the treatment of depression and agitation. The concept with AXS-05 is that dextromethorphan is pretty darn effective in treating depression, but has such poor bioavailability that it is hardly used. Bupropion synergistically improves the uptake of BM while providing baseline antidepressant effects. AXS-02 is an oral formulation of a well know bisphosphonate known to improve pain in CRPS and knee OA.

    I like the fact that Axsome has good insider ownership, plenty of cash, drugs with proven mechanisms of action, strong IP, and plenty of catalysts. Data from COAST-1 is expected in the Q3-2017. That's the first catalyst up for the company. CREATE-1 and STRIDE-1 are up in the Q4-2017 and Q1-2018, respectively. If the company goes 3-for-3, this stock will be north of $15.
     
  20. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    106
    Likes Received:
    4
    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) May 10, 2017

    https://www.networknewswire.com/net...y-rating-axsome-therapeutics-inc-nasdaq-axsm/

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
     

Share This Page